LENZ Therapeutics, Inc. (LENZ)
4.59
-0.09
(-1.92%)
USD |
NASDAQ |
Aug 24, 16:00
4.69
+0.10
(+2.18%)
Pre-Market: 08:26
LENZ Therapeutics Enterprise Value : -75.23M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -75.23M |
| August 21, 2026 | -72.40M |
| August 20, 2026 | -73.03M |
| August 19, 2026 | -64.86M |
| August 18, 2026 | -69.58M |
| August 17, 2026 | -68.95M |
| August 14, 2026 | -70.83M |
| August 13, 2026 | -74.92M |
| August 12, 2026 | -61.09M |
| August 11, 2026 | -55.75M |
| August 10, 2026 | -51.04M |
| August 07, 2026 | -51.04M |
| August 06, 2026 | -55.44M |
| August 05, 2026 | -53.87M |
| August 04, 2026 | -60.78M |
| August 03, 2026 | -62.51M |
| July 31, 2026 | -52.92M |
| July 30, 2026 | -38.47M |
| July 29, 2026 | -39.73M |
| July 28, 2026 | -34.70M |
| July 27, 2026 | -40.36M |
| July 24, 2026 | -47.27M |
| July 23, 2026 | -60.78M |
| July 22, 2026 | -51.67M |
| July 21, 2026 | -57.32M |
| Date | Value |
|---|---|
| July 20, 2026 | -63.61M |
| July 17, 2026 | -56.69M |
| July 16, 2026 | -66.12M |
| July 15, 2026 | -62.66M |
| July 14, 2026 | -64.55M |
| July 13, 2026 | -55.12M |
| July 10, 2026 | -43.81M |
| July 09, 2026 | -37.53M |
| July 08, 2026 | -26.85M |
| July 07, 2026 | -34.07M |
| July 06, 2026 | -43.50M |
| July 02, 2026 | -34.39M |
| July 01, 2026 | -37.53M |
| June 30, 2026 | -40.99M |
| June 29, 2026 | -77.11M |
| June 26, 2026 | -75.23M |
| June 25, 2026 | -84.95M |
| June 24, 2026 | -82.75M |
| June 23, 2026 | -77.42M |
| June 22, 2026 | -75.23M |
| June 18, 2026 | -64.88M |
| June 17, 2026 | -58.93M |
| June 16, 2026 | -53.28M |
| June 15, 2026 | -49.83M |
| June 12, 2026 | -45.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ocular Therapeutix, Inc. | 1.848B |
| Enveric Biosciences, Inc. | -2.747M |
| Liquidia Corp. | 6.160B |
| Aquestive Therapeutics, Inc. | 653.05M |
| Impact BioMedical, Inc. | 52.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.92M |
| Revenue (Quarterly) | 5.486M |
| Total Expenses (Quarterly) | 37.40M |
| EPS Diluted (Quarterly) | -1.017 |
| Gross Profit Margin (Quarterly) | 94.90% |
| Profit Margin (Quarterly) | -581.8% |
| Earnings Yield | -88.91% |
| Normalized Earnings Yield | -88.91 |